Stock Forecast

  Bellerophon Therapeutics, Inc. ( BLPH) Stock. Should you Buy or Sell?    $ 1.21

-0.01 (-0.83 %)



Bellerophon Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol BLPH
Price $1.21
Beta -0.118
Volume Avg. $38.89 thousand
Market Cap $11.55 M
52 Week Range $0.67 - $4.49


Bellerophon Therapeutics, Inc. opened the day at $1.21 which is -0.83 % on yesterday's close. Bellerophon Therapeutics, Inc. has a 52 week high of $4.49 and 52 week low of $0.67, which is a difference of $3.82. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $11.55 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Bellerophon Therapeutics, Inc. for $11.55 M, it would take 15 years to get your money back. Bellerophon Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Bellerophon Therapeutics, Inc. Stock Forecast - Is Bellerophon Therapeutics, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreBuy
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.803
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Bellerophon Therapeutics, Inc.


Price Book Value Ratio 0.941 Price To Book Ratio 0.941
Price To Sales Ratio 0.000 Price Earnings Ratio -0.803


How liquid is Bellerophon Therapeutics, Inc.


Current Ratio 3.118
Quick Ratio 2.997


Debt


Debt Ratio 0.307 Debt Equity Ratio 0.444
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Bellerophon Therapeutics, Inc.


Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

Date : 10/01/2022

Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped

The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.

Date : 20/12/2021

These Biotech Penny Stocks Exploded Today, Here's Why

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Date : 17/12/2021

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Date : 01/12/2021

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

Date : 07/09/2021





About Bellerophon Therapeutics, Inc.


CEO : Mr. Fabian Tenenbaum
Sector : Healthcare
Industry : Biotechnology

Website : https://bellerophon.com

Exchange : NASDAQ Capital Market

Description :

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.


My Newsletter

Sign Up For Updates & Newsletters